Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Seitz

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Cell Cycle (Georgetown, Tex.)|October 26, 2012
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancerFerenc G Rick, Stephan Seitz, Andrew V Schally, et al.
Archives of Gynecology and Obstetrics|August 5, 2018
Impact of a cervical dysplasia and its treatment on quality of life and sexual functionJudith Heinzler, Janina Brucker, Thomas Bruckner, et al.
Anti-Cancer Drugs|June 4, 2009
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibitionStephan Seitz, Andrew V Schally, Andrea Treszl, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinasesFerenc G Rick, Andrew V Schally, Luca Szalontay, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 13, 2006
Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivoMeike L Schipper, Christoph G U Riese, Stephan Seitz, et al.
Oncology Reports|October 25, 2008
Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonistStephan Seitz, Florian Hohla, Andrew V Schally, et al.
Archives of Gynecology and Obstetrics|October 31, 2018
Adherence to gynecological screening impacted by experienced orthodontic treatment in childhoodSarah Schott, Judith Heinzler, Nathalie Rippinger, et al.
Breast Cancer Research and Treatment|January 18, 2024
Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancerMaria Eleni Hatzipanagiotou, Miriam Pigerl, Michael Gerken, et al.
Cancer Letters|February 17, 2010
Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cellsFlorian Hohla, Stefan Buchholz, Andrew V Schally, et al.
Anti-Cancer Drugs|October 20, 2012
Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]Stephan Seitz, Stefan Buchholz, Andrew V Schally, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Cell Cycle (Georgetown, Tex.)|October 26, 2012
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancerFerenc G Rick, Stephan Seitz, Andrew V Schally, et al.
Archives of Gynecology and Obstetrics|August 5, 2018
Impact of a cervical dysplasia and its treatment on quality of life and sexual functionJudith Heinzler, Janina Brucker, Thomas Bruckner, et al.
Anti-Cancer Drugs|June 4, 2009
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibitionStephan Seitz, Andrew V Schally, Andrea Treszl, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinasesFerenc G Rick, Andrew V Schally, Luca Szalontay, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 13, 2006
Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivoMeike L Schipper, Christoph G U Riese, Stephan Seitz, et al.
Oncology Reports|October 25, 2008
Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonistStephan Seitz, Florian Hohla, Andrew V Schally, et al.
Archives of Gynecology and Obstetrics|October 31, 2018
Adherence to gynecological screening impacted by experienced orthodontic treatment in childhoodSarah Schott, Judith Heinzler, Nathalie Rippinger, et al.
Breast Cancer Research and Treatment|January 18, 2024
Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancerMaria Eleni Hatzipanagiotou, Miriam Pigerl, Michael Gerken, et al.
Cancer Letters|February 17, 2010
Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cellsFlorian Hohla, Stefan Buchholz, Andrew V Schally, et al.
Anti-Cancer Drugs|October 20, 2012
Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]Stephan Seitz, Stefan Buchholz, Andrew V Schally, et al.
Pageof 6